Stanford spins out virtual biotech run by 37,000 AI agents that designed a lung cancer therapy later validated in trials
burny_tech · x · 2026-11-10
A Stanford Medicine lab spun out a virtual biotech company staffed entirely by 37,000 AI agents — no lab space, no humans, no payroll. Built by biomedical data science associate professor James Zou and graduate student Harrison Zhang on top of their 2025 virtual lab, the agentic company covers the full drug development pipeline from target discovery to clinical trial design. It reportedly predicted drug trial success and independently designed a lung cancer therapy that was later validated in trials.
- Extends the earlier virtual lab, where AI scientists emulate an academic research lab
- Aims to test how far a fully agentic company can go on drug discovery's hardest problems
More from AGI Musings
- 2026 AI Forecasting Survey Update Collects Community Timelines — eli_lifland · 2026-11-10
- BlueDot Impact CEO: AI Safety's Biggest Gap Is a Lack of Entrepreneurs — luke_drago_ · 2026-11-10
- AI circles debate PhD value as OpenAI staff accused of academic disdain — niloofar_mire · 2026-11-10
- BlueDot CEO: AI Safety Talent All Wants OpenAI, Government Pipelines Lag — luke_drago_ · 2026-11-10
- Finite agents survive by compressing reality; calm is what staying in the predictive envelope feels like — mimi10v3 · 2026-11-10
- Op-ed: AI will pose questions no human can parse — we'll keep receiving answers we can't understand — r0ck3t23 · 2026-11-10